Guanabenz Acetate

醋酸胍那苄

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGuanabenz Acetate
Drug Alias Name胍那苄WytensWytensinWY-8678 acetateAP-713 (free base) +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors antagonists
TargetsAdrenergic receptors
Therapy Area/IndicationsEssential HypertensionMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis +[4] 
Global Approved IndicationsEssential Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1982/09/07
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesYokohama City University
Inactive CompaniesWyeth-AyerstNational Institute Of Neurological Disorders And Stroke
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsEssential HypertensionMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG